Iambic Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IAM | INDP | DMAC | CADL | AKTS | INBX | |
|---|---|---|---|---|---|---|
| Market cap | 635.17M | 439.70M | 580.78M | 692.49M | 845.42M | 1.28B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -2.4 | -14.4 | -14.5 | -7.1 | -9.9 |
| Price/book | -1.4 | 38.8 | 15.1 | 5.5 | 1.7 | -24.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −28.66% | +25.10% | +50.38% | +73.28% | −33.30% | −1.45% |
| Today | −0.67% | +1.85% | +7.70% | +2.61% | +1.74% | +7.01% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IAM news ›Bambusa Therapeutics (BBTX) sets $15-$17 range for $150 million Nasdaq IPO
As seen on the 24/7 Wall St. homepage on October 26, 2026. Bambusa sets $15-$17 range for $150 million Nasdaq IPO Bambusa Therapeutics just put a number on its Nasdaq debut: 9.375 million shares at $15 to $17, a $150 million raise with…
Bambusa Therapeutics prices upsized IPO at $16 per share
Bambusa Therapeutics (BBTX) priced its upsized initial public offering at $16 per share, offering 10.56M common shares. The company expects to raise ~$168.9M in gross proceeds before offering expenses. Underwriters have been granted a…
Aspen Neuroscience prices IPO at $15 per share
Aspen Neuroscience (ASPE) priced its IPO of 9.375M shares at $15 per share, expecting gross proceeds of ~$140.6M. - Aspen Neuroscience (ASPE) priced its IPO of 9.375M shares at $15 per share, expecting gross proceeds of ~$140.6M. - The…
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom
By Manya Saini and Niket Nishant The initial public offering would value the drugmaker at up to $805.8 million — towards the top of its indicated price range — based on the number of outstanding shares listed in its prospectus, a…
Iambic Therapeutics
This company recently went public with an IPO on Thursday, October 15th 2026. They issued 9,375,000 shares at $15.00 - $17.00 per share. We will continue to update data for IAM as it becomes available. Iambic’s technology platform is…
More from 1 other outlet
InMed Pharmaceuticals: ADAR1 funds buy 1,086 shares
InMed Pharmaceuticals Inc. (NASDAQ: INM) is a British Columbia-based drug developer focused on proprietary small molecule CB1/CB2 programs in Alzheimer’s, ocular and dermatological indications. - [Form 4] InMed Pharmaceuticals Inc. Insider…
InMed Pharmaceuticals: ADAR1 reports 17.2% stake
Healthcare Triangle, Inc. Announces 1-for-20 Reverse Stock Split as Part of Nasdaq Compliance Plan BlackRock Capital Allocation Term Trust (BCAT) Announces Results of its Rights Offering Greenland Energy Company Announces the Resignation…
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
ASHFORD HOSPITALITY TRUST ANNOUNCES $17 MILLION ADVISORY FEE WAIVER, SHARE PURCHASE COMMITMENT FROM ASHFORD INC. AND TERMINATION OF ATM PROGRAM WISeQey Issues CEO Letter to Shareholders: Building an Intelligent, Secure Platform for the…
Iambic Therapeutics, Inc. Common Stock (IAM) Option Chain
Nasdaq - Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. These symbols will be available throughout the site during your session. - Type a instrument or…
Iambic Therapeutics Stock Rallies After $150 Million IPO
Iambic began trading on the Nasdaq Global Select Market under the ticker IAM and finished its debut session up 18%. The shares settled at $18.91, above the $16 issue price, putting the market value at about $896 million using the…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- tradingview.com27
- stocktitan.net17
- marketscreener.com5
- briefs.co2
- seekingalpha.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 73 articles, not a forecast.